Alto Neuroscience, Inc.
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company specializing in the development of precision medicines for neuropsychiatric disorders. Founded in 2019 and headquartered in California, the company leverages its proprietary Precision Psychiatry Platform™ to measure brain biomarkers through analysis of electroencephalography (EEG) activity, neurocognitive assessments, wearable data, genetics, and behavioral patterns. Its core products include clinical-stage drug candidates such as ALTO-100, ALTO-101, ALTO-202, ALTO-203, and ALTO-300, which target major depressive disorder, bipolar depression, schizophrenia, treatment-resistant depression, and post-traumatic stress disorder. Alto's platform integrates artificial intelligence-derived brain biomarkers to personalize treatment approaches for individual patients, aiming to improve clinical response and outcomes. In the past two years, Alto Neuroscience has made significant advances including a successful FDA meeting for ALTO-207, a treatment for treatment-resistant depression, which has enabled acceleration of its development. The company secured $50 million in private placement financing in 2025 to support the initiation of a Phase 2b clinical trial by mid-2026 and plans to
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
Alto Neuroscience (NYSE:ANRO) Shares Gap Down Following Analyst Downgrade
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements
Alto Neuroscience Announces $120 Million Private Placement Financing
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights
Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression
Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology
Alto Neuroscience (NYSE:ANRO) Trading Down 6% – Here’s Why
Alto Neuroscience, Inc. $ANRO Shares Sold by AWM Investment Company Inc.
Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08